A Prophylactic Role for Creatine in Hypoxia?

Elisabeth Engl, Mona M. GarvertJournal of Neuroscience 2015 · DOI · OpenAlex

Abstract: The brain requires ∼20% of the body's total energy. When the body is deprived of energy, such as during hypoxia and in pathologies involving an altered energy metabolism, the brain's function can be severely and irreversibly disrupted. However, humans routinely cope with transient hypoxia, for example, at high altitudes or during specific medical procedures. This paper explores the potential for oral creatine supplementation to serve as a prophylactic neuroprotective agent against the cognitive deficits induced by acute hypoxia.

Introduction

The human brain is a metabolic outlier, consuming a disproportionate amount of the body's energy. Under conditions of low oxygen (hypoxia), the oxidative metabolism required to generate adenosine triphosphate (ATP) is compromised. This failure leads to a cascade of negative effects: the breakdown of ionic gradients, impaired synaptic transmission, and potential neuronal death.

While creatine—a compound known for its role in rapid ATP replenishment—has shown promise in animal models of neurodegeneration, human clinical trials for conditions like ALS or Huntington’s have often yielded disappointing results. This discrepancy suggests that the timing of administration may be critical to its efficacy. This review examines whether prophylactic creatine use can protect cognitive performance in healthy humans during acute hypoxia.

Methods

To investigate the preventative potential of creatine, Turner et al. (2015) conducted a double-blind, randomized, placebo-controlled crossover study involving 15 healthy participants. The protocol involved a seven-day supplementation phase of either 20g/day of oral creatine or a placebo, separated by a five-week washout period.

Acute hypoxia was induced by having participants breathe 10% oxygen for 90 minutes, simulating an altitude of approximately 4.4 km (roughly the summit of Mt. Whitney). The researchers utilized three primary measurement tools:

  1. Magnetic Resonance Spectroscopy (MRS): To quantify changes in brain creatine and phosphocreatine levels.
  2. Transcranial Magnetic Stimulation (TMS): To measure corticomotor excitability (the ease with which neurons in the motor cortex fire).
  3. Cognitive Battery: A suite of neuropsychological tests, including the Stroop, Shifting Attention, and Continuous Performance tests, to evaluate mental performance under stress.

Results

The study found that oral supplementation successfully increased total brain creatine and phosphocreatine levels by an average of 9.2%. Under hypoxic conditions, participants on the placebo experienced significant declines in alertness and executive function. However, those supplemented with creatine showed a significant rescue of "complex attention" scores, effectively mitigating the cognitive decline seen in the control group.

Furthermore, TMS data revealed that creatine increased corticomotor excitability during hypoxia compared to the placebo group. This indicates that creatine alters the brain's cellular response to low-oxygen stress, maintaining neural firing capacity even when energy supply is limited.

Discussion

The findings highlight two critical concepts regarding creatine’s role in neuroprotection:

The Timing Hypothesis

A major takeaway is that timing matters. In failed clinical trials for neurodegenerative diseases, creatine was typically administered after the disease had already manifested. In this study, as in successful animal models, creatine was present before the metabolic insult. This suggests that creatine’s role is primarily prophylactic, serving as a "brain buffer" that must be in place before the energy crisis begins.

Beyond Energy Buffering

Creatine is traditionally viewed as a short-term energy reserve that stores high-energy phosphates to quickly replenish ATP. However, the math of energy metabolism suggests that supplemental creatine would only provide a few additional seconds of ATP. Because the cognitive benefits in this study lasted for the full 90 minutes of hypoxia, the authors propose that creatine may have a neuromodulatory role. It may directly stimulate the $Na^+/K^+$-ATPase pump or enhance glutamate uptake, providing sustained protection that exceeds simple energy replenishment.

Limitations and Future Directions

While promising, the study is limited by its small sample size (n=15). The authors noted that the cognitive benefits were most apparent when scores were pooled into a "complex attention" factor, suggesting that individual test results might not have reached statistical significance on their own. Additionally, the exact mechanism—the transition from "energy buffer" to "neuromodulator"—remains theoretical.

Future research should involve larger clinical trials focusing on populations at risk for transient hypoxia, such as high-altitude workers or patients undergoing surgeries that may compromise cerebral oxygenation. Isolating the specific neuromodulatory actions of creatine will be essential for developing it as a standard clinical intervention.

Conclusion

Creatine supplementation offers a potential "brain buffer" against the cognitive impairments caused by acute hypoxia. By increasing brain creatine levels prior to an energy crisis, individuals may be able to maintain higher levels of complex attention and neural excitability, suggesting a vital prophylactic role for this common supplement in neuroprotection.

Summary updated

Abstract

The brain requires ∼20% of the body's total energy. When the body is deprived of energy, such as during hypoxia and in pathologies involving an altered energy metabolism, the brain's function can be severely and irreversibly disrupted. However, humans routinely cope with transient hypoxia, for
BibTeX
@article{engl2015prophylactic,
  author = {Elisabeth Engl and Mona M. Garvert},
  title = {{A Prophylactic Role for Creatine in Hypoxia?}},
  journal = {Journal of Neuroscience},
  year = {2015},
  doi = {10.1523/jneurosci.1195-15.2015},
}
Figure